预防性3小时梯度输注方案可最大程度降低卡铂过敏反应风险——一项前瞻性研究
本研究前瞻性观察既往无铂类过敏史的妇科癌症患者在接受二线及以上卡铂再治疗时,采用3小时梯度输注联合预处理预防过敏反应(HSR)的频率。99例患者共接受611个周期卡铂治疗,仅11个周期(1.8%)发生HSR,其中8例为1-2级(8.1%),3例为3级(3%);6例患者在暂停输注并额外预处理后再次尝试该方案成功且未再发生HSR。
要点
- 99例妇科癌症患者二线及以上卡铂再治疗,共611个周期,采用3小时梯度输注联合预处理。
- 仅11个周期(1.8%)发生HSR,8例为1-2级(8.1%),3例为3级(3%)。
- 6例发生HSR的患者经暂停输注、症状完全缓解并额外预处理后,再次尝试该方案成功且未再发生HSR。
核心结论
- 在这项前瞻性研究中,预防性3小时梯度输注速率联合适当预处理与需要二线及以上卡铂再治疗的妇科癌症患者中较低的HSR频率相关。
研究设计与样本
- 前瞻性研究,纳入99例既往无铂类HSR史、接受二线及以上卡铂再治疗的妇科癌症患者,所有患者均接受皮质类固醇和抗组胺药预处理后以3小时梯度输注卡铂。
主要发现
- 99例患者包括卵巢癌71例、输卵管癌9例、腹膜癌9例及其他妇科癌症10例(子宫癌5例、妇科来源腹部癌5例)。
- 共611个周期卡铂治疗,其中单药210个周期、联合方案401个周期。
- HSR仅记录于11个周期(1.8%),共涉及11例患者;8例为1或2级反应(8.1%),仅3例为3级反应(3%)。
- 发生HSR的11例患者中,6例在暂停输注且HSR症状完全缓解后,采用该输注方案并额外预处理再次尝试成功,无HSR再发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Aim of this study was observation of hypersensitivity reaction (HSR) frequency by using a 3-hour graduated infusion protocol with appropriate premedication as a prophylactic measure in patients with gynecological cancer receiving carboplatin retreatment in second line or above. None of the patients had experienced HSRs to platinum previously. METHOD: All the patients in this study received premedication with corticosteroids and anti-histamines followed by carboplatin as 3-hour graduated infusion. Carboplatin was administered either as monotherapy or in combination with other chemotherapeutic agents. RESULTS: Ninety-nine patients with ovarian (n=71), fallopian tube (n=9), peritoneal (n=9) and other gynecological cancers (5 uterine cancer, 5 abdominal cancer of gynecological origin) were retreated by a total of 611cycles of carboplatin administered as monotherapy (210cycles) or combination regime (401cycles). HSRs were recorded in only 11cycles (1.8%) in a total of 11 patients. While 8 of these patients had grade 1or 2 reactions (8.1%), only 3 patients had grade 3 reactions (3%). After pause in the infusion and complete resolution of HSR symptoms, an attempt of retreatment using this infusion protocol with extra premedication was successful in 6 of these patients without any reoccurrence of HSRs. CONCLUSION: In this prospective study, we report that prophylactic 3-hour graduated infusion rate with appropriate premedication is associated with low frequency of HSRs in gynecological cancer patients requiring carboplatin retreatment in second line or above.
引用
- Koul A, Forsland EL, Bjurberg M, et al. Prophylactic 3-hour graduated infusion schedule minimizes risk of carboplatin hypersensitivity reactions - A prospective study. Gynecol Oncol. 2017. PMID: 29208369. doi:10.1016/j.ygyno.2017.11.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。